NCT00401219View on ClinicalTrials.gov

Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

November 30, 2006

Study Completion Date

February 28, 2007

Conditions

Estrogen Replacement Therapy

Interventions

DRUG

conjugated estrogens/progestin (MPA)

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00401219 - Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation | Biotech Hunter | Biotech Hunter